Versiti has announced the acquisition of Quantigen, a specialty lab based in Fishers, Indiana.
The acquisition expands Versiti’s portfolio across the drug and medical device development pathway and adds complementary expertise supporting clinical trials in infectious disease, women’s health and gastrointestinal and reproductive health. Financial terms of the deal were not disclosed.
Based in Fishers, Indiana, Quantigen is a contract research organization (CRO) and a patient diagnostic laboratory whose services are focused on supporting the development of novel diagnostic tests and medical devices.
Versiti is a world-class blood health organization with locations across the Midwest. Headquartered in Milwaukee, Versiti provides solutions in transfusion medicine, transplantation and blood-related diseases. Versiti has more than 2,300 employees in Illinois, Indiana, Michigan, Ohio, Texas and Wisconsin.
According to data captured in the LevinPro HC database, this transaction marks the 19th CRO transaction of the year. This also marks Versiti’s first transaction of 2023. In 2022, it expanded its clinical trials services with the purchase of Ethical and Independent Review Services in July for an undisclosed price.
